327 related articles for article (PubMed ID: 32699213)
21. Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
Laetsch TW; Liu X; Vu A; Sliozberg M; Vido M; Elci OU; Goldsmith KC; Hogarty MD
Cell Death Dis; 2014 Feb; 5(2):e1072. PubMed ID: 24556687
[TBL] [Abstract][Full Text] [Related]
22. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1.
Lee YC; Chen YJ; Huang CH; Chang LS
Apoptosis; 2017 Mar; 22(3):406-420. PubMed ID: 27757735
[TBL] [Abstract][Full Text] [Related]
23. Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
Sancho M; Leiva D; Lucendo E; Orzáez M
FEBS J; 2022 Oct; 289(20):6209-6234. PubMed ID: 34310025
[TBL] [Abstract][Full Text] [Related]
24. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
25. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
Wu X; Luo Q; Zhao P; Chang W; Wang Y; Shu T; Ding F; Li B; Liu Z
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2961-2966. PubMed ID: 30718431
[TBL] [Abstract][Full Text] [Related]
26. DDX3 interacts with USP9X and participates in deubiquitination of the anti-apoptotic protein MCL1.
Lai MC; Chen YP; Li DA; Yu JS; Hung HY; Tarn WY
FEBS J; 2022 Feb; 289(4):1043-1061. PubMed ID: 34606682
[TBL] [Abstract][Full Text] [Related]
27. miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.
Xu W; Li Z; Zhu X; Xu R; Xu Y
Med Sci Monit; 2018 Dec; 24():8812-8821. PubMed ID: 30518744
[TBL] [Abstract][Full Text] [Related]
28. Proteasome-associated deubiquitinases and cancer.
Mofers A; Pellegrini P; Linder S; D'Arcy P
Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
30. Programming cancer cells for high expression levels of Mcl1.
Ertel F; Nguyen M; Roulston A; Shore GC
EMBO Rep; 2013 Apr; 14(4):328-36. PubMed ID: 23478333
[TBL] [Abstract][Full Text] [Related]
31. β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1.
Hassan S; Pullikuth A; Nelson KC; Flores A; Karpova Y; Baiz D; Zhu S; Sui G; Huang Y; Choi YA; D'Agostino R; Hemal A; von Holzen U; Debinski W; Kulik G
Mol Cancer Res; 2020 Dec; 18(12):1839-1848. PubMed ID: 32928910
[TBL] [Abstract][Full Text] [Related]
32. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
[TBL] [Abstract][Full Text] [Related]
33. Staurosporine resistance in inflammatory neutrophils is associated with the inhibition of caspase- and proteasome-mediated Mcl-1 degradation.
Hornstein T; Lehmann S; Philipp D; Detmer S; Hoffmann M; Peter C; Wesselborg S; Unfried K; Windolf J; Flohé S; Paunel-Görgülü A
J Leukoc Biol; 2016 Jan; 99(1):163-74. PubMed ID: 26310832
[TBL] [Abstract][Full Text] [Related]
34. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
35. A novel autophagy-independent, oncosuppressive function of BECN1: Degradation of MCL1.
Elgendy M; Minucci S
Autophagy; 2015; 11(3):581-2. PubMed ID: 25837021
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis.
Liu Y; Xu X; Lin P; He Y; Zhang Y; Cao B; Zhang Z; Sethi G; Liu J; Zhou X; Mao X
J Biol Chem; 2019 Mar; 294(12):4572-4582. PubMed ID: 30718275
[TBL] [Abstract][Full Text] [Related]
37. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
[TBL] [Abstract][Full Text] [Related]
38. MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73.
Widden H; Kaczmarczyk A; Subedi A; Whitaker RH; Placzek WJ
Cell Death Dis; 2020 Nov; 11(11):946. PubMed ID: 33144577
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
40. JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1.
Wu X; Luo Q; Zhao P; Chang W; Wang Y; Shu T; Ding F; Li B; Liu Z
Cell Death Differ; 2020 Jan; 27(1):55-70. PubMed ID: 31043700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
